XOMA Royalty

XOMA · NASDAQ

Price unavailable right now.

No price history for this range.

XOMA analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.
  • Strong buy0
  • Buy3
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $45.39

Low
$39.39
High
$52.50

Upgrades and downgrades

The latest rating actions, newest first

XOMA analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Apr 30, 2026DowngradeBuy → Neutral
HC Wainwright & Co.Mar 20, 2026MaintainsBuy
Leerink PartnersFeb 24, 2026MaintainsOutperform
HC Wainwright & Co.Dec 11, 2025MaintainsBuy
Leerink PartnersDec 11, 2025MaintainsOutperform
LUCID CAPITAL MARKETSDec 9, 2025InitiatesBuy

The case for and against

Updated May 30, 2026

Bull case

XOMA Royalty is expected to continue growth through the acquisition of early to mid-stages clinical assets, with a strong focus on key products such as Vabysmo, Ojemda, and Miplyffa. The company has shown a sustained profitability and well-managed OPEX, with year-end cash of $83 million (excluding restricted cash). XOMA also has a strong cash position of $130.6 million, allowing them to leverage further deals in the future. Their in vivo evidence and animal studies have shown long-term expression of COL7, which is a positive indication for their product FCX-007. Additionally, XOMA's expanded relationship with Takeda brings in nine new assets and strengthens their overall portfolio. Despite recent negative news on some assets, XOMA's diversified risk profile and growing number of assets give them a strong downside buffer and potential for further valuation upside.

Bear case

XOMA Royalty is set to see a negative financial impact due to an increase in share count and diluted EPS, despite the potential boost from mezagitamab's differentiated mechanism of action and projected 5.5% royalty rate. Challenges in ITP and IgAN markets from competitors and the requirement for differentiation could lead to a limited market share for mezagitamab, making it critical for its commercial success. Furthermore, while XOMA recently expanded its royalty opportunity for mezagitamab, the undisclosed increase in royalty is estimated to be only 1.5%, and XOMA is also entitled to milestone payments from Takeda.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.